Carcinoma of unknown primary: Molecular tumor board-based therapy
CA Cancer J Clin
.
2022 Nov;72(6):510-523.
doi: 10.3322/caac.21748.
Epub 2022 Aug 25.
Authors
Aditya V Shreenivas
1
,
Shumei Kato
2
,
Jingjing Hu
3
,
Catherine Skefos
4
,
Jason Sicklick
5
,
Razelle Kurzrock
1
6
Affiliations
1
Division of Hematology and Medical Oncology, Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA.
2
Medical Oncology, Department of Medicine, Moores Cancer Center, University of California-San Diego, San Diego, California, USA.
3
Department of Pathology, Moores Cancer Center, University of California-San Diego, San Diego, California, USA.
4
Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
5
Division of Surgical Oncology, Moores Cancer Center, University of California-San Diego, San Diego, California, USA.
6
Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA.
PMID:
36006378
PMCID:
PMC10180180
DOI:
10.3322/caac.21748
No abstract available
MeSH terms
Carcinoma*
Humans
Neoplasms, Unknown Primary* / pathology
Neoplasms, Unknown Primary* / therapy
Precision Medicine
Grants and funding
R01 CA226803/CA/NCI NIH HHS/United States